Is Your Breast Pain a Heart Health Warning? 3 Important Facts Every Woman Should Know
By Dr. Tori Hudson, N.D.
Breast Pain- also known as mastalgia is a common concern seen regularly in clinical practice and is a frequent reason for visits to both primary care and gynecology offices. Mastalgia can be defined as the discomfort, tenderness, or pain in one or both breasts.3 While often benign, it can cause significant distress for patients who may fear a serious underlying condition such as breast cancer.2 Understanding its causes, evaluation, and available treatment options is essential for effective management. Emerging evidence supports molecular iodine as a safe and effective adjunctive therapy for cyclic mastalgia, particularly in women who do not respond to standard conservative measures. Clinical trials have shown that molecular iodine at approximately 3–6 mg per day, taken over 3–6 months, can significantly reduce both breast pain and nodularity in cyclic mastalgia
There are two major types of mastalgia providers should be aware of:
- Cyclic Mastalgia3
- Pain that correlates with the menstrual cycle, typically peaking during the luteal phase and resolving with the onset of menses.
- This pain usually affects both breasts
- Non-cyclic Mastalgia3
- Pain unrelated to the menstrual cycle, which may be constant or intermittent and may affect one or both breasts.
- Common causes include breast cysts, fibroadenomas, infections such as mastitis, prior injury or trauma, and inflammation.
- Cyclic and non-cyclic mastalgia should not be confused with Extramammary pain3
- A pain perceived in the breast but originating from another structure, such as the chest wall, ribs, or spine.
- Musculoskeletal issues such as costochondritis or chest wall muscle injures are common causes.
The most common causes of mastalgia to be aware of include hormonal fluctuations, fibrocystic breast changes, medications, trauma or musculoskeletal pain, infections, or inflammatory conditions or rarely, breast cancer.2 Shifts in estrogen and progesterone in the luteal phase of the cycle can cause glandular tissue proliferation, engorgement, and tenderness.3 These are normal hormonal fluctuations, but the breast is more sensitive to these changes. Fibrocystic breast changes are benign tissue changes that can be worsened by higher dietary fats, caffeine, and often include nodularity and discomfort. Some medications may cause mastalgia including SSRIs, oral contraceptives, and menopause hormone therapy (although usually symptom should lead the practitioner to lower the dose of estrogen if the symptoms persist).3 Breast cancer is an uncommon cause of mastalgia, but evaluation is warranted if the pain is focal, persistent, or associated with amass or nipple changes or discharge.2
As a provider you should be able to adequately assess mastalgia and its underlying cause. Symptoms reported include:3
- Aching, heaviness, or burning sensation
- Localized tenderness or diffuse pain
- Swelling or lumpiness
- A possible mass or nodule present
- Pain severity affecting quality of life
The clinical approach should be a thorough history including onset, relation to the menstrual cycle, medication review, diet review and trauma history. A physical exam includes breast and axillary palpation and chest wall assessment. For imaging, consider whether an ultrasound and/or mammogram are warranted.2
Current conventional treatment options for mastalgia typically start with oral or topical NSAIDS and proper bra fitting.2 For more severe cases and fortunately rarely, even danazol, bromocriptine or tamoxifen is considered, but they come with a greater likelihood of unpleasant side effects.2
Natural minded practitioner treatment options typically include research-based vitamin E and/or evening primrose oil and/or chaste tree berry, and/or iodine. Let’s talk about the iodine and breast connection.3
IODINE AND THE BREAST
Iodine is an essential mineral that the human body utilizes for various functions, primarily thyroid hormone synthesis. 1,3 In day to life, iodine is commonly found in iodized salt and seaweed. The recommended daily intake in adults is ~150 mcg/day with the tolerable upper intake level (UL) for adults is about 1,100 mcg/day.1
The mammary glands have a high affinity for iodine, second only to the thyroid.1,6 Iodine is actively transported into breast tissue, particularly during puberty, pregnancy, and lactation, when breast development and milk production require it.6 Iodine supports normal epithelial cell differentiation in the breast and adequate levels help maintain healthy breast architecture and may reduce abnormal proliferation associated with fibrocystic changes.3
Low iodine levels may make breast tissue more sensitive to circulating estrogens, leading to cyclic pain, tenderness, and nodularity.3
Current Research Findings in Animal Studies
- Iodine deficiency (either dietary or via blockade of uptake) causes mammary gland changes in rats that closely resemble features of fibrocystic disease in humans: cystic spaces, hyperplasia of alveolar / lobular epithelium, increased fibrosis, sometimes atypia or dysplasia.6,9
- Estrogen or hormonal stimulation magnifies the effects of iodine deficiency: when estradiol is given to iodine-deficient rats, the mammary tissue shows more pronounced abnormal growth (hyperplasia, cystic secretion, etc.).6,9
- Form of iodine matters: molecular iodine (I₂) often has greater benefit in reducing hyperplasia / fibrosis and restoring more normal histologic features than iodide (I⁻) in many of the studies.6,9
- Pain is not directly measured in most animal models; structural / histologic changes are used as proxies. Thus, translation to symptom relief (mastalgia) in humans is plausible but not fully established by animal data alone.6,9
Current Research Findings in Human Studies
- Efficacy at higher than dietary doses: Many of the human trials that showed clinically meaningful improvement used iodine doses above typical dietary intake, sometimes several mg/day (supraphysiologic levels).4,5
- Form matters: Molecular iodine (I₂) seems more effective in many studies than iodide or bound/protein-bound forms when assessing both subjective symptoms (pain, tenderness) and objective findings (nodularity, fibrosis).4,5
- Improvements in nodularity may precede pain relief: In some studies, structural changes (nodules, fibrosis) reduce before or more reliably than pain scores. Nodularity reduction may correlate with pain reduction.4,5
- Placebo effects are significant: Studies of breast pain/mastalgia commonly show high placebo responses, which can make detecting differences in pain reduction more challenging.4,5
- Safety profile generally acceptable in trials, but with caveats: In many studies, mild thyroid function changes (e.g., transient TSH elevation) are noted, especially at higher iodine intakes. Long-term safety, especially in people with underlying thyroid disease, remains less well characterized.4,5
Top Two Studies to Reference:
| Study | Design/Population | Iodine Form & Dose | Outcomes on Breast symptoms |
| “The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia”4 | Randomized, double-blind, placebo-controlled; 111 euthyroid women with moderate-to-severe cyclic breast pain and ≥25% fibrosis of both breasts; duration 6 months
|
Molecular iodine; 1.5, 3.0, or 6.0 mg/day vs placebo, over 6 months. | The 3.0 and 6.0 mg/day doses produced statistically significant reductions in overall pain, tenderness, and nodularity compared to placebo. At 5 months, both physician- and patient-assessed improvements in pain in those higher-dose groups. The 6 mg/day group had >50% of participants with clinically significant pain reduction
|
| “A Randomized Controlled Multicenter Trial of an Investigational Liquid Nutritional Formula…” (GLA + iodine + selenium)5 | RCT, double-blind; 188 women with cyclic breast pain + fibrocystic breast changes (experimental group n ≈ 93, control ≈ 95); 3 menstrual cycles (~3 months).
|
Experimental formula: 1 g gamma-linolenic acid + 750 µg iodine + 70 µg selenium daily vs control formula lacking those. | Main findings: breast pain scores decreased similarly in both experimental and control groups (no statistically significant between-group difference for pain). However, nodularity was significantly reduced in the experimental (GLA+iodine+selenium) group (p = 0.03). Also, among women who continued to use OTC pain medications, those in the experimental group reduced their consumption more than control (p = 0.02)
|
Clinical considerations and approaches to using iodine for mastalgia
- Form:
- Molecular iodine (I₂) is often used in clinical trials and appears more effective for breast pain/nodularity than iodide alone.4,5
- Typical Dose Range:
- Trials found 3–6 mg/day (in divided doses) produced significant reductions in pain and nodularity over 5–6 months. Can start as low as 1.5mg/day can also show some benefit.4,5
- Duration:
- Most studies used 3–6 months as the treatment period.
- Improvements often seen by 3 months; some patients continue longer-term under supervision.4,5
- Safety Considerations:
- Monitor thyroid function (TSH, free T4) every 3–6 months.
- Avoid in patients with active hyperthyroidism or iodine sensitivity.
- Discontinue if TSH rises persistently or symptoms of thyroid dysfunction occur.4,5
Conclusion:
Available data suggests that molecular iodine administered at approximately 3–6 mg/day may provide clinically meaningful relief in women with cyclic mastalgia associated with fibrocystic breast changes. In trials of euthyroid women, tolerance was good, and no major thyroid‐related adverse effects were reported, but thyroid monitoring is prudent. Because the body of evidence remains limited, larger, and longer‐duration studies are needed to better confirm efficacy and optimize dosing.
REFERENCES
- Ghent WR, et al. Iodine replacement in fibrocystic disease of the breast. Can J Surg. 1993;36(5):453-460.
- Hubbard TJ, Sharma A, Ferguson DJ. Breast pain: assessment, management, and referral criteria. Br J Gen Pract. 2020;70(697):419-420.
- Kataria K, Dhar A, Srivastava A, Kumar S, Goyal A. A systematic review of current understanding and management of mastalgia. Indian J Surg. 2014;76(3):217-222.
- Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J. 2004;10(4):328-336.
- Mansel RE, et al. A randomized controlled multicenter trial of an investigational liquid nutritional formula in women with cyclic breast pain associated with fibrocystic breast changes. Breast J. 2018;24(6):1010-1016.
- Nagasawa H, Mitani F, Nomura T, et al. Iodine and mammary cancer: preventive effect of chronic administration of elemental iodine in Sprague-Dawley rats. Jpn J Cancer Res. 1993;84(9):997-1001.
- Stoddard FR 2nd, Brooks AD, Eskin BA, Johannes GJ. Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci. 2008;5(4):189-196.
- Tahir MT, Vadakekut ES, Shamsudeen S. Mastalgia. In: StatPearls [Internet]. StatPearls Publishing; 2025.
- Teng CT, et al. Molecular iodine inhibits the development and growth of MNU-induced rat mammary tumors. Mol Med. 2009;15(7-8):321-327.
- Thomas DB, et al. Iodine and the breast: epidemiological evidence. Cancer Causes Control. 1993;4(1):33-36.
Dr. Tori Hudson, N.D.
Dr. Tori Hudson, Naturopathic Physician, graduated from the National College of Naturopathic Medicine in 1984 and has since served the college in many capacities including Professor, Medical Director, Associate Academic Dean, and Academic Dean. She is currently an adjunct clinical professor at NUNM, Sonoran University of Health Sciences, and Bastyr University. Dr. Hudson has been in practice for more than 40 years, is the medical director of her clinic, A Woman’s Time, in Portland, OR, and is the director of product research and education for Vitanica. She is also the founder and co-director of Naturopathic Education and Research Consortium, a nonprofit for accredited naturopathic residencies.
Dr. Hudson has recently been appointed as a faculty member of the Fellowship in Integrative Health and Medicine, Academy of Integrative Health and Medicine.
Dr. Hudson was awarded the 1990 President’s Award from the American Association of Naturopathic Physician’s for her research in the field of women’s health care, the 1999 prestigious Naturopathic Physician of the Year award, the 2003 NCNM Alumni Pioneer Award and the 2009 Natural Products Association NW Pioneer Award. In 2012, she was inducted into the NCNM Hall of Fame and in 2016 the Oregon Association of Naturopathic Physician awarded her the Living Legend Award. Most recently, in May 2021, she was awarded the honorary Fredi Kronenberg Excellence in Research and Education in Botanicals for Women’s Health Award from the American Botanical Council. This award is presented to a researcher, educator, and/or clinician who furthers the scientific study, education, and clinical use of medicinal plants and phytomedicines for women’s health conditions.
She is a nationally recognized author, speaker, educator, researcher and clinician. Dr. Hudson serves on several editorial boards, advisory panels and as a consultant to the natural products industry.
Dr. Hudson is the Program Director for the Institute of Women’s Health and Integrative Medicine, as well as the Co – Director, Naturopathic Education and Research Consortium , a Naturopathic Residency Program.
